Supercharging immune cells to battle blood cancer: breakthrough in cancer immunotherapy

A new study reveals a groundbreaking approach to immunotherapy, demonstrating that blocking the interaction between the CD300A receptor and phosphatidylserine (PS) significantly enhances the ability of human natural killer (NK) cells to lyse hematologic malignancies (HMs). 

Read More